TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19889809

Group type: EXPERIMENTAL
Intervention: High (n-3)LCPUFA beverage (1 g fat/kg body weight)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low (n-3)LCPUFA beverage (1 g fat/kg body weight)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High (n-3)LCPUFA beverage
Number of subjects: 8

Group type: COMPARATOR
Intervention: High and low (n-3)LCPUFA beverages
Number of subjects: 8
Study: 16940036

Group type: EXPERIMENTAL
Intervention: Mono-protease inhibitor use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual-protease inhibitor use
Number of subjects: 0
Study: 16319804

Group type: EXPERIMENTAL
Intervention: Humalog Mix25 (Mix25)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Maximum dose glibenclamide (control)
Number of subjects: 73
Study: 11732662

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3500
Study: 9426992

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 146
Study: 3813951

Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (Amicar), 100 mg/kg every four hours, up to a maximum of 30 g/d for five days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo for five days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (Amicar)
Number of subjects: 34
Study: 2665584

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 1,500 micrograms/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31613965

Group type: EXPERIMENTAL
Intervention: Metformin during pregnancy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: PCOS
Number of subjects: 145
Study: 30969136

Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study: 28558864

Group type: EXPERIMENTAL
Intervention: APAP 6-20 cm H2O
Number of subjects: 56

Group type: COMPARATOR
Intervention: CPAP at recommended pressure
Number of subjects: 56
Study: 25990545

Group type: EXPERIMENTAL
Intervention: Achilles decompression and debridement augmented with FHL transfer
Number of subjects: 39

Group type: COMPARATOR
Intervention: Achilles decompression and debridement alone (control group)
Number of subjects: 39
Study: 23437093

Group type: EXPERIMENTAL
Intervention: Stair descending exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stair ascending exercise
Number of subjects: 20
Study: 22198589

Group type: EXPERIMENTAL
Intervention: Human fetal striatal transplantation (HFST)
Number of subjects: 0
Study: 19485597

Group type: EXPERIMENTAL
Intervention: Coping and Promoting Strength program (CAPS; n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait list control condition (WL; n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coping and Promoting Strength program (CAPS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait list control condition (WL)
Number of subjects: 40
Study: 17046384

Group type: EXPERIMENTAL
Intervention: Tanaproget 0.1 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tanaproget 0.3 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tanaproget 1 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tanaproget 3 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tanaproget 7 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tanaproget 15 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-fat meal with tanaproget
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 14685868

Group type: EXPERIMENTAL
Intervention: Painful contractions with 6% hypertonic saline injection
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition (no pain)
Number of subjects: 10
Study: 11502234

Group type: EXPERIMENTAL
Intervention: Stearic acid-rich meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oleic acid-rich meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Linoleic acid-rich meal
Number of subjects: 6
Study: 9362186

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme supplementation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8487073

Group type: EXPERIMENTAL
Intervention: Radiotherapy (55 Gy over a total of 6 1/2 to 7 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiotherapy plus CCNU (100 mg/sq m every 6 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 2963742

Group type: EXPERIMENTAL
Intervention: alpha-human atrial natriuretic polypeptide (alpha-hANP) infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 31249394

Group type: EXPERIMENTAL
Intervention: Urine protein:creatinine ratio (UPCR)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: UPCR cut-off value of 2.4
Number of subjects: 154

Group type: COMPARATOR
Intervention: 24-hour urine protein
Number of subjects: 154
Study: 28165608

Group type: EXPERIMENTAL
Intervention: Glaucoma personal record
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard clinical care (Control)
Number of subjects: 122
Study: 26714488

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 23730858

Group type: EXPERIMENTAL
Intervention: Foot reflexology treatment for 1 week in three sessions following haemodialysis, each session lasting approximately 30 minutes
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no reflexology treatment)
Number of subjects: 80
Study: 21262048

Group type: EXPERIMENTAL
Intervention: 8 weekly home visits focused on improving caregiver sensitivity
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 67
Study: 19793860

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA; 60 mg ferrous fumarate and 400 microg folic acid)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Folic acid (FA; 400 microg)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Number of subjects: 272
Study: 16409326

Group type: EXPERIMENTAL
Intervention: Group 1: immersion in 24% H(2)O(2) for 10 min and silanization for 60 s
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Group 2: immersion in 10% H(2)O(2) for 20 min and silanization for 60 s
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Group 3: immersion in 4% hydrofluoric acid gel for 60 s and silanization for 60 s
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Group 4: silanization of the post surface for 60 s and application of the bonding agent G-Bond
Number of subjects: 110

Group type: COMPARATOR
Intervention: Group 5: silanization of the post surface for 60 s (control group)
Number of subjects: 110
Study: 15243010

Group type: EXPERIMENTAL
Intervention: Controlled-release methylphenidate (MPH), 1.0 mg/kg, once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 12
Study: 11804430

Group type: EXPERIMENTAL
Intervention: ketoconazole (400 mg daily) followed by clomiphene (100 mg/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: clomiphene without ketoconazole pretreatment
Number of subjects: 97
Study: 8988791

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8237838

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 674

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 674
Study: 3307550

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ketamine (2 mg/kg)
Number of subjects: 50
Study: 31723996

Group type: EXPERIMENTAL
Intervention: Ibrutinib and Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: FCR (Fludarabine, Cyclophosphamide, and Rituximab)
Number of subjects: 0
Study: 28437262

Group type: EXPERIMENTAL
Intervention: Lumbar Puncture Simulator II (Kyoto Kagaku, Kyoto, Japan)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lumbar Epidural Injection Trainer (Erler‐Zimmer, Lauf, Germany)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Normal Adult Lumbar Puncture/Epidural Tissue (Simulab Corp., Seattle, Washington, USA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Banana
Number of subjects: 55
Study: 26077237

Group type: COMPARATOR
Intervention: Bevacizumab monotherapy 10 mg/kg IV every 2 weeks
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg IV every 2 weeks and temsirolimus 25 mg IV every week
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg IV every 2 weeks and sorafenib 200 mg orally twice daily
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg twice daily and temsirolimus 25 mg IV weekly
Number of subjects: 361
Study: 23599320

Group type: EXPERIMENTAL
Intervention: 3 mL of autologous whole blood injected
Number of subjects: 53

Group type: COMPARATOR
Intervention: Needling only (control group)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 53
Study: 20832982

Group type: EXPERIMENTAL
Intervention: Caregiver-assisted coping skills training (CST)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Education/support involving the caregiver
Number of subjects: 233
Study: 18299548

Group type: EXPERIMENTAL
Intervention: Bare-arm group (n = 180)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Sleeved-arm group (n = 196)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 376
Study: 16518424

Group type: EXPERIMENTAL
Intervention: Topical histamine dihydrochloride (HDC) gel
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 45
Study: 14618033

Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 522

Group type: COMPARATOR
Intervention: Rhythm control strategy
Number of subjects: 522

Group type: COMPARATOR
Intervention: Rhythm control therapy
Number of subjects: 522
Study: 10755495

Group type: EXPERIMENTAL
Intervention: Metformin (2.5 g/d) + Rosiglitazone (4 mg/d)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Metformin (2.5 g/d) + Rosiglitazone (8 mg/d)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Metformin (2.5 g/d) + Placebo
Number of subjects: 348
Study: 8969976

Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex) treatment
Number of subjects: 0
Study: 1624019

Group type: EXPERIMENTAL
Intervention: Superovulation with buserelin acetate, human menopausal gonadotropins (hMG), and human chorionic gonadotropin (hCG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Expectant management (6 months)
Number of subjects: 49
Study: 6743467

Group type: EXPERIMENTAL
Intervention: Kinidin durules
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Longacor
Number of subjects: 6
Study: 31315577

Group type: EXPERIMENTAL
Intervention: Motivational sentence in cover letter
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Motivational sentence mentioning alcohol
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Motivational sentence mentioning stress
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Motivational sentence mentioning sex
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Motivational sentence (general)
Number of subjects: 25000

Group type: COMPARATOR
Intervention: Control group (generic letter)
Number of subjects: 25000
Study: 30427505

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BT-A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 36
Study: 25460342

Group type: EXPERIMENTAL
Intervention: PRISM system
Number of subjects: 300

Group type: COMPARATOR
Intervention: Binder condition
Number of subjects: 300
Study: 22880943

Group type: EXPERIMENTAL
Intervention: HIV/AIDS Symptom Management Manual self-care strategies
Number of subjects: 222

Group type: COMPARATOR
Intervention: Nutrition manual (control)
Number of subjects: 222
Study: 21427328

Group type: EXPERIMENTAL
Intervention: Reduced tube voltage (80 or 100 kVp depending on BMI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard tube voltage (100 or 120 kVp depending on BMI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard tube voltage
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reduced tube voltage
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reduced tube current
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard tube current
Number of subjects: 50
Study: 18703571

Group type: EXPERIMENTAL
Intervention: Developmental care (DC)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard care (C)
Number of subjects: 179
Study: 17969466

Group type: EXPERIMENTAL
Intervention: Sleep restriction combined with 0.035 g/dL low-dose alcohol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sleep restriction combined with 0.025 g/dL low-dose alcohol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal sleep without alcohol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sleep restriction alone (4 hours)
Number of subjects: 21
Study: 13680286

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with oral PSK (3 g per day) followed by oral 5‐FU (200 mg/body per day)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Intermittent chemotherapy with oral 5‐FU (200 mg per day) followed by 4‐week rest
Number of subjects: 446
Study: 11471517

Group type: EXPERIMENTAL
Intervention: Linezolid (Zyvox‐‐Pharmacia)
Number of subjects: 0
Study: 9514527

Group type: EXPERIMENTAL
Intervention: GB virus C co-infection
Number of subjects: 160

Group type: COMPARATOR
Intervention: Hepatitis C infection alone
Number of subjects: 160
Study: 9346380

Group type: EXPERIMENTAL
Intervention: Exercise renal rehabilitation program (ERRP) consisting of 3 weekly sessions for 6 months
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Exercise renal rehabilitation program (ERRP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sedentary control status
Number of subjects: 31
Study: 1783082

Group type: EXPERIMENTAL
Intervention: Diamorphine 2.5 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diamorphine 5 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diamorphine 7.5 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo elixir
Number of subjects: 14
Study: 7113880

Group type: EXPERIMENTAL
Intervention: 10°C water bath exposure
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 14°C water bath exposure
Number of subjects: 31

Group type: COMPARATOR
Intervention: 22°C water bath exposure
Number of subjects: 31

Group type: COMPARATOR
Intervention: 26°C water bath exposure
Number of subjects: 31

Group type: COMPARATOR
Intervention: 34°C water bath exposure
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 31
Study: 30925876

Group type: EXPERIMENTAL
Intervention: CBG-CS-2 (1.68 g/day for 8 weeks)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 79
Study: 30076607

Group type: EXPERIMENTAL
Intervention: INTERGROWTH-21st
Number of subjects: 9409

Group type: EXPERIMENTAL
Intervention: National Institute of Child Health and Human Development
Number of subjects: 9409

Group type: EXPERIMENTAL
Intervention: WHO fetal growth standards
Number of subjects: 9409
Study: 26771888

Group type: EXPERIMENTAL
Intervention: Carrying at least one minor allele of rs2069762 (G) in IL2
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Carrying two copies of the minor allele of rs1800871 (T) of IL10
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Carrying the minor allele of rs486907 (A) in RNASEL
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Genetic risk score from the three SNPs possibly associated with inflammation
Number of subjects: 205
Study: 25114296

Group type: EXPERIMENTAL
Intervention: IDegLira + metformin
Number of subjects: 413

Group type: COMPARATOR
Intervention: IDeg + metformin
Number of subjects: 413
Study: 22934754

Group type: EXPERIMENTAL
Intervention: Topical rapamycin (0.003% and 0.015%)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (no rapamycin)
Number of subjects: 23
Study: 20358335

Group type: EXPERIMENTAL
Intervention: Transulnar percutaneous pinning
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transarticular bridging external fixation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ulnar styloid fracture with radius fracture treated by external fixation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ulnar styloid fracture with radius fracture treated by pinning
Number of subjects: 100

Group type: COMPARATOR
Intervention: No ulnar styloid fracture with radius fracture treated by pinning or external fixation
Number of subjects: 100
Study: 17234653

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (immediate clamping)
Number of subjects: 40
Study: 16186438

Group type: EXPERIMENTAL
Intervention: Primary angioplasty in high-risk group
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Fibrinolysis in high-risk group
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Primary angioplasty in low-risk group
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Fibrinolysis in low-risk group
Number of subjects: 1527
Study: 12153372

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) use
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Demographic characteristics, military service, military-related health outcomes, and physician-diagnosed health complaints
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Current high daily stress, perceived negative impact of military life on physical or mental health, and physician-diagnosed chronic illnesses
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Predictor variables from regression analysis
Number of subjects: 508
Study: 9752983

Group type: EXPERIMENTAL
Intervention: High dairy intake (six dairy servings/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low dairy intake (<0.5 serving of dairy products/day)
Number of subjects: 40
Study: 7948057

Group type: EXPERIMENTAL
Intervention: Experimental day-treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving standard inpatient care
Number of subjects: 0
Study: 3354317

Group type: EXPERIMENTAL
Intervention: Three-flanged nail
Number of subjects: 21

Group type: COMPARATOR
Intervention: Three screws
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hammering of the nail
Number of subjects: 21
Study: 29433562

Group type: EXPERIMENTAL
Intervention: Insulin pump therapy for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control group (NC)
Number of subjects: 0
Study: 27455955

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly for 12 weeks followed by etanercept 25 mg twice weekly for 12 weeks (ETN-ETN)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly plus acitretin 10 mg twice daily for 24 weeks (ETN-ACT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acitretin 10 mg twice daily for 24 weeks (ACT)
Number of subjects: 60
Study: 24558091

Group type: EXPERIMENTAL
Intervention: Visual assessment of lesions using FLAIR imaging
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Threshold of relative signal intensity (rSI) of 1.20
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Incorporation of rSI measurements into visual evaluation
Number of subjects: 143
Study: 22633033

Group type: EXPERIMENTAL
Intervention: Specialised care of cognitive behaviour therapy with sound-focused tinnitus retraining therapy
Number of subjects: 492

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 492
Study: 21098771

Group type: EXPERIMENTAL
Intervention: Combination training (aerobic and resistance training)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: All exercise groups
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Combination training
Number of subjects: 262

Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 262
Study: 18455287

Group type: EXPERIMENTAL
Intervention: Glucose containing drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15966464

Group type: EXPERIMENTAL
Intervention: SPP301 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPP301 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPP301 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPP301 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPP301 (all doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12820458

Group type: EXPERIMENTAL
Intervention: Screening for infectious foci (chest and sinus roentgenograms, ENT surgeon visit, dentist visit)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 73
Study: 10689613

Group type: EXPERIMENTAL
Intervention: Interviewed by case managers
Number of subjects: 78

Group type: COMPARATOR
Intervention: Interviewed by external researchers
Number of subjects: 78
Study: 8929751

Group type: EXPERIMENTAL
Intervention: Drug use in case of illness during pregnancy before admission to hospital for delivery
Number of subjects: 300

Group type: COMPARATOR
Intervention: Drug administration under delivery
Number of subjects: 300

Group type: COMPARATOR
Intervention: Drug therapy of chronic diseases in pregnancy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Treatment of nursing women
Number of subjects: 300
Study: 1626679

Group type: EXPERIMENTAL
Intervention: 0.5% prilocaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.5% chloroprocaine
Number of subjects: 10